

11
OBCD

Please type a plus sign (+) in this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

14

Application Number

09/665,510

Filing Date

September 19, 2000

First Named Inventor

Ralph T. KUBO

Group Art Unit

To Be Assigned

Examiner Name

To Be Assigned

ENCLOSURES (check all that apply)

- | | | |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return postcard |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input checked="" type="checkbox"/> Information Disclosure Statement; PTO form 1449; copy of European Search Report; and 60 references | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/ Incomplete Application | | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

Remarks

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name

Bruce D. Grant
Registration No. 47,608

Signature

Date


November 15, 2001

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on November 15, 2001.

Garee A. Haney

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.




PATENT
Docket No. 399632000325

H6

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on November 15, 2001.


Garee A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ralph T. KUBO et al.

Serial No.: 09/665,510

Filing Date: September 19, 2000

For: HLA BINDING PEPTIDES AND THEIR
USES

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith, except documents Nos. 2, 9, 28 and 42, which will follow. The Examiner is requested to make these documents of record.

The documents Nos. 15, 23 and 64, listed on the attached Form PTO-1449 were cited in a Search Report (copy attached) directed to a counterpart international or foreign application.

This Information Disclosure Statement is submitted:

- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of * is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **399632000325**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 15, 2001

Respectfully submitted,

By: _____

Bruce D. Grant
Registration No. 47,608

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7962
Facsimile: (858) 720-5125



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 399632000325	Application Number 09/665,510
	Applicant Ralph T. KUBO et al.	
	Filing Date September 19, 2000	Group Art Unit To Be Assigned
	Mailing Date: November ___, 2001	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
1.	04/1998	5,736,142	Sette et al.	424	185.1		
2.	03/2000	6,037,135	Kubo et al.	435	7.27		
3.	06/2000	6,075,122	Cheever et al.	530	352		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
4.		Alexander et al., J. Immunol. (1997) 159:4753-4761
5.		Altfeld et al., J. Virol. (2001) 75:1301-1311
6.		Benjamin et al., Nature (1991) 351:74-77
7.		Bergmann et al., J. Virol. (1994) 68:5306-5310
8.		Bertoni et al., J. Clin. Invest. (1997) 100:503-513
9.		Boel et al., Immunity (1995) 2:167
10.		Boon et al., Int. J. Cancer (1993) 54:177-180
11.		Castellanos et al., Gynecologic Oncology (2001) 82:77-83
12.		Castellanos et al., Oncology/Hematology (2001) 39:133-138
13.		Chang et al., J. Immunol. (1999) 162:1156-1164
14.		Chen and Parham, Nature (1989) 337:743-745
15.		Culmann et al., J. Immunol. (1991) 146(5):1560-1565
16.		Del Val et al., Cell (1991) 66:1145-1153
17.		Diepolder et al., J. Virol. (1997) 71(8):6011-6019

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632000325	Application Number 09/665,510
Applicant	Ralph T. KUBO et al.
Filing Date September 19, 2000	Group Art Unit To Be Assigned
Mailing Date: November ___, 2001	

18.	Ding et al., Immunity (1998) 8:403-411
19.	Doolan et al., Immunity (1997) 7:97-112
20.	Doolan et al., J. Immunol. (2000) 165:1123-1137
21.	Eisenlohr et al., J. Exp. Med. (1992) 175:481-487
22.	Gambacorti-Passerini et al., Clin. Cancer Res. (1997) 3:675-683
23.	Gavioli et al., Proc. Natl. Acad. Sci. USA (1992) 89:5862-5866
24.	Gonzalez et al., Parasite Immunology (2000) 22:501-514
25.	Ishioka et al., J. Immunol. (1999) 162:3915-3925
26.	Jameson and Bevan, Eur. J. Immunol. (1992) 22:2663-2667
27.	Kast et al., J. Immunol. (1994) 152:3904-3912
28.	Kast et al., Eur. J. Immunol. (1993) 23:1189-1192
29.	Kawakami et al., J. Immunol. (1995) 154:3961-3968
30.	Kawashima et al., Human Immunol. (1998) 59:1-14
31.	Kozlowski et al., J. Exp. Med. (1992) 175:1417-1422
32.	Lamonica et al., Hepatology (1999) 30:1088-1098
33.	Lipford et al., J. Immunol. (1993) 150:1212-1222
34.	Lustgarten et al., Human Immunology (1997) 52:109-118
35.	Niedermann et al., Immunol. Rev. (1999) 172:29-48
36.	Niedermann et al., Proc. Natl. Acad. Sci. USA (1996) 93:8572-8577
37.	Prezzi et al., Eur. J. Immunol. (2001) 31:894-906
38.	Rehermann et al., J. Clin. Invest. (1996) 97:1655-1665
39.	Ressing et al., J. Immunol. (1995) 154:5934-5942
40.	Rivoltini et al., J. Immunol. (1995) 154:2257-2265
41.	Ruppert et al., Cell (1993) 74:929-937
42.	Sarobe et al., Eur. J. Immunol. (1991) 21:1555-1558
43.	Scognamiglio et al., J. Immunol. (1999) 162:6681-6689
44.	Sette et al., J. Immunol. (1994) 153:5586-5592
45.	Sette and Sidney, Curr. Opin. Immunol. (1998) 10:478-482
46.	Sette et al., in Persistent Viral Infections, Ahmed and Chen (Eds.), John Wiley & Sons (1999)
47.	Sette et al., Immunodominance and Breadth of Cellular Responses (2001) In Press
48.	Shastri et al., J. Immunol. (1995) 155:4339-4346

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632000325	Application Number 09/665,510
Applicant	Ralph T. KUBO et al.
Filing Date September 19, 2000	Group Art Unit To Be Assigned
Mailing Date: November ___, 2001	

49.	Sherman et al., J. Exp. Med. (1992) 175:1221-1226
50.	Snoke et al., J. Immunol. (1993) 151:6815-6821
51.	Tangri et al., Journal of Experimental Medicine (2001) In Press
52.	Threlkeld et al., J. Immunol. (1997) 159:1648-1657
53.	Tsai et al., J. Immunol. (1997) 179:1802
54.	Van Der Most et al., J. Immunol. (1996) 157:5543-5554
55.	Van Der Most et al., Virology (1997) 71:5110-5114
56.	Van Der Most et al., Virology (1998) 240:158-167
57.	Vitiello et al., J. Immunol. (1996) 157:5555-5562
58.	Wentworth et al., Eur. J. Immunol. (1996) 26:97-101
59.	Wilson et al., J. Virol. (2001) 75:4195-4207
60.	Wizel et al., J. Clin. Invest. (1998) 102:1062-1071
61.	Yewdell and Bennick, Annu. Rev. Immunol. (1999) 17:51-88
62.	Yoon et al., Virus Research (1998) 54:23-29
63.	York and Rock, Annu. Rev. Immunol. (1996) 14:369-396
64.	Zhang et al., Proc. Natl. Acad. Sci. USA (1993) 90(6):2217-2221

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.